Contact Information: Contacts: Investor Relations. Andrew Barwicki 516.662.9461 Website: www.nanologix.net
NanoLogix Applies for Provisional Patent Application For Innovative Treatment of Severe Sepsis
| Source: NanoLogix
SHARON, PA -- (MARKET WIRE) -- February 20, 2007 -- NanoLogix, Inc. (PINKSHEETS : NNLX ) announced
today that it has filed a provisional patent application with the U.S.
Patent Office titled, "Antimicrobial Action of a Silver-Coated Nanotubular
Dialysis Device."
This provisional patent application is based around a new and unique
methodology for treating severe sepsis and septic shock. The incidence of
severe sepsis and septic shock is the major factor in over two hundred
thousand deaths per year in the United States. During the past decades
billions of dollars have been spent in developing treatment strategies for
this major cause of morbidity and mortality. Almost all treatment
strategies have been centered around the utilization of intravenous
antibiotics. However, even today 20-35% of patients with severe sepsis and
40-60% of patients with septic shock die within thirty days, with further
deaths occurring within the first six months of illness. Due to the fact
that almost all of these patients must be treated in intensive care units,
the cost of treating a single patient costs up to $10,000 per day, and the
total cost to the American health care system is many billions of dollars
per annum.
The NanoLogix invention treats bacteremia and septic shock by utilizing a
silver nanoparticle-coated nanotubular dialysis unit for killing pathogenic
micro-organisms present in a patient's blood stream. Prior to making this
application NanoLogix scientists investigated this novel methodology
against two bacterial strains (E.coli and Staphylococcus aureus) and one
fungal strain (Candida albicans). In multiple experiments the pathogenic
load of the micro-organisms went from colonies that were too numerous to
count, down to zero or a very dramatically reduced number of colonies.
Mitchell S. Felder, M.D., the CEO and Chairman of the Board of NanoLogix,
Inc. stated, "This is both a fascinating as well as truly innovative
approach to conquering this major cause of hospital deaths worldwide. We
hope to accelerate our investigation of this methodology, and are currently
seeking to partner with a major university and/or health care organization.
With further success and development, this technique could truly
revolutionize the treatment of infectious diseases and save countless
lives."
About NanoLogix, Inc.:
NanoLogix is an industry innovator in the research, development and
commercialization of nano-biotechnologies, applications and processes. The
Company owns or has the rights to 32 patented technologies. The Company is
currently focused on the production of hydrogen from agricultural
feedstock, industrial wastewater and municipal waste streams to create new
sources of energy. NanoLogix is presently operating a hydrogen bioreactor
at Welch's Food and has recently signed an agreement with the City of Erie
Wastewater Treatment Plant for a prototype bioreactor installation.
Additionally, NanoLogix develops and markets diagnostic test kits for use
in early detection of infectious human diseases such as cancer, cystic
fibrosis and AIDS, and owns a patent for the non-toxic induction of
apoptosis ('cell suicide') for the treatment of cancer. For more
information on the Company, visit http://www.nanologix.net.
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the assumptions
on which such statements are based. Prospective investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results
may differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or revise
forward-looking statements to reflect changed assumptions, the occurrence
of unanticipated events or changes to future operating results.